

Clean Seed Capital Group

06:30 04 Aug 2020

Proactive's latest virtual event highlights a trio of rising stars in medicine and agriculture

A select group of small cap stocks will join Proactive's Steve Darling at the digital financial news organization's upcoming virtual investor conference on at 1pm ET on Tuesday, August 4.

The virtual One2One Investor Forum event is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and some of North America's most innovative businesses.

The three companies participating on Tuesday are medical device developer BioSig Technologies Inc (NASDAQ:BSGM), gene therapy company Genprex Inc (NASDAQ:GNPX) and agriculture technology company Clean Seed Capital Group (CVE:CSX).

Building a better ECG machine

BioSig Technologies, based in Westport, Connecticut, is commercializing a biomedical signal processing platform called PURE EP, which is designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals.

The company is also doing its part to combat the coronavirus, through its subsidiary ViralClear Pharmaceuticals Inc. ViralClear is currently enrolling patients for a Phase 2 trials of its drug merimepodib, an orally administered therapy that has demonstrated broad-spectrum in-vitro antiviral activity, including strong activity against SARS-CoV-2 (the virus that causes the COVID-19 disease) in cell cultures.

CEO and chairman Kenneth Londoner will present on behalf of the company.

READ: BioSig Technologies subsidiary ViralClear forms Scientific Advisory Board with two industry veterans experienced as both regulators and corporate executives

"With our stock up 34% year-to-date and the strongest balance sheet in the company's history, we are well-positioned for continuous value creation on behalf of our shareholders," Londoner said in a recent statement. "Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP System's ongoing and future installations. Our pharmaceutical subsidiary ViralClear sees a steady patient enrollment across many hospital sites."

Clean Seed's SMART farming technologies

Clean Seed Capital Group is working full tilt at driving technology advancements in farming. The Canadian company has created the CX-6 SMART Seeder, a machine with the ability to plant six different crops, at three different depths with military precision.

Price: 0.33

Market Cap: \$25.18 m

1 Year Share Price Graph



Share Information

Code: CSX

Listing: TSX-V

52 week High Low
0.44 0.14

Sector: Manufacturing & engineering

Website: www.cleaneedcapital.com

Company Synopsis:

Clean Seed continues to be on the leading edge of an agricultural revolution through the development of the new highly advanced CX-6 SMART Seeder™. The CX-6 SMART Seeder™ offers an unrivalled level of precision in modern no-seeding and planting and is being considered the future of farming.

action@proactiveinvestors.com

The beauty of the CX-6 SMART Seeder for farmers and agriculture scientists is that the hulking high-output planter is wirelessly controlled through a tablet running on the company's intuitive SeedSync software system.

WATCH: Clean Seed to deploy their patented SMART technologies to modernize the agricultural sector

Burnaby, British Columbia-based Clean Seed has not stopped with the CX-6 SMART seeder, having just rolled out a highly advanced, lighter version of its planter. The company teamed up with joint venture partner North Dakota-based Norwood to give farmers the new Smart Seeder Max and Smart Seeder Max S.

"This partnership optimizes our ability to deliver growth, rapidly and reliably with an invested partner. Our teams are also collaborating on several additional opportunities that will further differentiate our offerings," CEO Graeme Lempriere said.

A lung cancer therapy and a possible cure for diabetes

Genprex is developing a robust pipeline of drugs, headlined by its non-small cell lung cancer (NSCLC) drug candidate GPX-001, formerly known as Oncoprex. The drug works by interrupting cell signaling pathways that cause the replication and proliferation of cancer cells.

The drug received Fast Track Designation from the US Food and Drug Administration (FDA) for use in combination with AstraZeneca's drug Tagrisso in late-stage lung cancer patients with epidermal growth factor receptor (EGFR) mutations whose tumors progress on Tagrisso alone.

READ: Genprex boss Rodney Varner gives second live interview on nationally syndicated TV and radio show the 'Big Biz Show'

The trial with Tagrisso is expected to be initiated in early 2021, and the company is also planning a clinical trial in combination with Keytruda, a cancer drug from Merck & Co Inc (NYSE:MRK).

The Austin-based company is also working on a preclinical diabetes gene therapy candidate, GPX-002, that it claims may have the potential to cure Type 1 and Type 2 diabetes.

CEO and Chairman Rodney Varner will present an update on the company's pipeline, including both GPX-001 and GPX-002, beginning at 1:40 pm ET.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Clean Seed Capital Group named herein, including the promotion by the Company of Clean Seed Capital Group in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).